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Abstract. Studies were carried out to determine the effectiveness of treating murine
viral leukemia by combining statolon therapy with irradiation and transplantation
therapy. The experimental design involved inoculating Rauscher leukemia-infected
mice with statolon, a potent interferon inducer, prior to lethal whole-body irradiation
and following hematopoietic cell transplantation. The data show that treating the
leukemic animals in this manner resulted in positive responses from all indices of
leukemia development investigated. These responses included a 42% decrease in
spleen weight at autopsy, a 21% increase in survival at 30 days, and significantly
decreased white blood cell counts and spleen weight during the treatment period.
Although the effect of the combination therapy was not permanent and further re-
finement of the experimental protocol is necessary, it appears to be a promising method
of treating viral leukemia.
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Storb et al (1973) have suggested that
leukemia patients receiving whole body
irradiation and hematopoietic cell trans-
plantation be treated with interferon
following irradiation. The basis for their
suggestion was the known blocking effect
of interferon on tumor virus replication
and cell transformation. They hypoth-
esized that if a leukemic agent is present
in the patient and is transmitted to the
susceptible donor cells, perhaps treat-
ment with interferon may inhibit this
(hypothetical) human leukemia virus and
prevent it from transforming the donor
cells.
One way of testing the hypothesis of
Storb et al is to use their treatment pro-
tocol to treat a known viral leukemia in
an animal model. Several animal models
could be used for this evaluation, but
Rauscher murine leukemia is particularly
suitable for several reasons. First of all,
we have shown that Rauscher leukemia
recurs in mice in a manner similar to that
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observed in the treatment of human acute
lymphoblastic leukemia, when lethal
whole body irradiation is followed by
hematopoietic cell transplantation (Kuh-
nert et al 1974). Further, the reinduc-
tion of the Rauscher leukemia has been
shown to occur in the donor cells (Kuh-
nert et al 1974), and, studies in our lab-
oratory (OKunewick et al 1972, OKune-
wick and Erhard 1973) and by others
(Kufe et al 1972) have shown that
Rauscher leukemia is a good model for
studying the etiology of viral leukemia.
Accordingly, the purpose of this in-
vestigation was to evaluate the hypothe-
sis of Storb and coworkers by treating
Rauscher viral leukemia with statolon, a
potent interferon inducer, in conjunction
with irradiation and hematopoietic cell
transplantation. Earlier studies showed
that irradiation and transplantation ther-
apy was capable of slowing the develop-
ment of murine viral leukemia (OKune-
wick et al 1973a). Likewise, statolon
therapy was extensively used to treat
viral leukemia and proved to be effective
under certain experimental conditions
(Wheelock et al 1973), but no animal
studies combining these 2 therapeutic
techniques have been reported.
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MATERIALS AND METHODS
X-Irradiation. Recipient mice were exposed
to 1100 R of x-rays with a G.E. Maxitron 300
x-ray unit operating at 275 kV and 20 mA with
a half value layer of 1.8 mm Cu. The exposure
rate was approximately 60 R/min measured
within the mouse holders. A Victoreen model
570 dosimeter employing a 100 R probe was
utilized to calculate R/min. The total dose
was measured for three 1 minute periods, cor-
rected for temperature and pressure, and the
average R/min calculated. Mice were exposed
to x-rays in groups of 10 in a plastic holder in
which they were free to move.
Rauscher Leukemia Virus (RL V). Fifty SED
50 units RLV suspension were injected intra-
peritoneally into 12 week old mice. The prepa-
ration and assay of the Rauscher virus stock
have been previously described (OKunewick
etal 1972, 1973b).
Animals. Female SJL/J mice were utilized
as recipient hosts and male SJL/J mice as do-
nors for the hematopoietic cell transplants.
They were obtained from Jackson Laboratories
at the age of 8 weeks, housed 5 to a cage in
filter covered cages, and maintained on auto-
claved food and acid water. At 12 weeks, both
the experimental and control mice were irradi-
ated with 1100 R and within 2 hours of irradia-
tion received an injection of spleen cells. Fol-
lowing transplantation, the mice were main-
tained 2 per cage.
Cell Transplantation. Donor spleen cell sus-
pensions were made by cutting open the spleens
of four to six 11-week-old male mice and gently
forcing the cells out of the capsule into sterile
Hank's solution (Mg and Ca free). The cells
were then broken down further into a single
suspension by repeated aspiration through a 25
gauge needle. After evaluating the number of
nucleated cells per ml using a Coulter Counter,
an appropriate dilution was made so that 0.5 ml
of the cell suspension contained 3 x 107 nucleated
cells. Recipient mice were injected with 0.5
ml of this cell suspension via the tail vein.
Vesicular Stom.atitus Virus (VSV). Vesicular
stomatitis virus (Indiana strain) was grown in
chick embryo fibroblast cultures. The in-
fected culture was subjected to 3 cycles of
freezing and thawing in a dry ice and acetone
bath. One ml aliquots were placed in sterile
vials and stored at —70 °C until use. This
virus preparation was found to contain 1000
tissue culture infecting doses (TCID50) per ml
when titrated on mouse L cell monolayer
cultures.
Cell Cultures. Mouse L cells (L-929) em-
ployed for the assay of interferon were obtained
from the American Type Culture Collection.
Cells were grown in a growth medium consisting
of TC Minimal Medium Eagle, Earle BSS
(MEM) supplemented with L-glutamine, fetal
calf serum and the antibiotic gentamicin (1, 10,
0.5 ml per 100 ml of medium respectively).
Maintenance medium was the same as the
growth medium except the fetal calf scrum
concentration was reduced to 4 ml per 100 ml
of medium.
Interferon Assay. The method employed for
assay of interferon was similar to that described
by Wheelock (1967). The serum samples to be
tested were diluted in growth medium, and
1 ml of each dilution was added to 1 day old
cultures of mouse L cells grown to incomplete
monolayers in screw cap culture tubes. After
20 hours of incubation at 37 °C, the cultures
were washed once with 4 ml of Dulbecco's
phosphate buffered solution. To each tube, 1
ml of warm protein-free growth medium was
added and then 1 ml of cold growth medium
containing 1000 TCID50 of vescular stomatitis
virus was inoculated. Cultures were con-
sidered to be protected when less than 10% of
the cells showed cytopathic effects at a time
when more than 75% of control cells exhibited
cytopathic effects.
Interferon titers are expressed as reciprocals
of the highest dilution of the serum employed,
1 ml of which protected cultures against chal-
lenge with standard doses of VSV. No serum
was tested at less than 1:10 dilution.
Stalolon. Statolon was supplied by Eli Lilly
& Co. (Lot 354-1080B-220) and was dissolved
in 1% sodium bicarbonate 2 hours prior to
inoculation of the mice (5 mg/mouse I.P.). It
was injected 25 hours prior to irradiation (13
days after RLV inoculation) and 15 days after
irradiation and transplantation (29 days after
RLV inoculation).
RESULTS
Effect of Combination Therapy on Spleen Weight
Figure 1 illustrates the effect of statolon
treatment on the spleen weight of 1100 R
irradiated and spleen cell transplanted
DAYS AFTER RLV INOCULATION
FIGURE 1. Effect of statolon on the
splenomegalic response to Rauscher leu-
kemia in 1100 R irradiated and spleen cell
transplanted mice. Irradiation and trans-
plantation were performed on day 14
(dashed arrow) and statolon was injected
on days 13 and 29 (solid arrows). Each
data point represents the mean =±= S. E. of
10-17 mice.
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mice over a period of 44 days following
RLV inoculation. The gradual increase
in spleen weight observed up to day 7
and the rapid increase observed from day
7 to day 14 are typical of Rauscher
leukemia development and have often
been used to assess the effectiveness of
various types of therapy on viral leukemia
(OKunewick 1972, Chirigos et al 1973).
On day 14 all of the mice received 1100 R
irradiation; thus, the rapid decrease in
spleen weight from day 14 to day 21 was
also expected. The leukemic mice treated
with statolon prior to irradiation and
transplantation, however, showed a
greater decrease in spleen weight on day
21 (7 days post-irradiation) than the un-
treated leukemic mice. Furthermore,
up to day 37 (23 days post-irradiation),
mice in the statolon treated group con-
tinued to have lower spleen weights than
the group treated with irradiation and
blood cell level of the untreated leukemic
mice (table 1). This slow increase in
the WBC level during the first 2 weeks
of RLV infection has been reported by
others (Markoe and OKunewick 1973).
On day 14, the statolon treated leukemic
mice did not show an increase in periph-
eral white cells. Apparently the injec-
tion of statolon slowed the WBC pro-
duction of the experimental group. Also
noticeable on day 14 was a decrease in
the WBC count of control mice treated
with statolon. On day 21, all groups of
mice were found to have greatly decreased
WBC counts. This finding is attribut-
able to treatment with a high level of
radiation and spleen cell trnasplantation
on day 14. Also apparent on day 21 and
on days 26 and 30 was the lower WBC
counts of the statolon treated as com-
pared to the untreated leukemic mice.
These differences were statistically sig-
TABLE 1
Effect of statolon on white blood cell increase in 1100 R irradiated and spleen cell
transplanted* mice with Rauscher leukemia.
Days after
RLV
Inoculation
7
14
21
26
30
37
44
Days
after -
X-ray
— 7
0
7
12
16
23
30
No RLV
6,311=*=
6,766±
501 ±
724
691
128
9,591 ±1634
4,825± 627
(n)
(16)t
(12)
(ID
(16)
(5)
Exper imental Group
No RLV-
Statolon**
7,528=*
1,154=±
268 =±
7,868 =t
5,144=±
= 445
= 188
= 30
= 1054
= 541
-l-
(n)
(10)
(9)
(2)
(6)
(o)
RLV
5,219± 766
7,401 ±1386
895± 162
7,829 ±1467
30,042 ±3196
40,228 ±7366
68,843 ±8304
(n)
(9)
(15)
(ID
(9)
(14)
(8)
(17)
RLV+
Statolon**
4,475± 651
4,019± 750
321 ± 41
2,991 ± 688
11,643± 2318
40,653 ± 7854
50,287 ±12506
(n)
(10)
(15)
(14)
(9)
(14)
(19)
(14)
*1100 R irradiation and spleen cell transplant occurred on day 14.
**Statolon was injected on days 13 and 29. RLV = Rauscher leukemia virus.
tMean±S.E.
spleen cell transplantation alone. The
differences observed on days 21, 26, and
30 were found to be statistically sig-
nificant (P<0.05). On days 37 and 44,
the spleen weights of the Rauscher leu-
kemic mice were similar regardless of
earlier statolon treatment.
Effect of Combination Therapy on Peripheral
White Cell Counts
The effect of statolon treatment on the
peripheral white blood cell increase in
irradiated and spleen cell transplanted
mice with Rauscher leukemia showed
(on day 14) an increase in the white
nificant (P<0.05). The observed dif-
ferences are apparently attributable to
treatment of the leukemic mice with
statolon; however, the effect of statolon
was not permanent, and a further in-
crease in the WBC count was observed
on days 37 and 44.
Effect of Combination Therapy on Spleen
Weight at Autopsy
One of the most readily recognizable
effects of Rauscher leukemia is spleno-
megaly (Chirigos et al 1973). This para-
meter is often used to assess the effective-
ness of various types of therapy on viral
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TABLE 2
Effect of statolon on terminal spleen weight of
1100 R irradiated and spleen cell transplanted
Treatment
No. of Spleen Weight
Mice at Autopsy (gm)
No RLV** 19
No RLV+Statolon 18
RLV 19
RLV+Statolon 27
0.0756 ±0.0108*
0.0617 ±0.0053
0.7981 ±0.1463
0.4558 ±0.0479
*Mean±S.E.
*RLV = Rauscher leukemia virus.
leukemia and table 2 shows the mean
autopsy spleen weights of the various
experimental groups of mice in this study.
Since each group was treated identically
with irradiation and transplantation of
the same number of hematopoietic cells,
the observed differences should be at-
tributable to treatment with statolon.
Comparing the statolon treated control
mice with the untreated control mice, a
slight decrease in mean spleen weight
can be seen but this difference is not
statistically significant. When compar-
ing the average spleen weights of the
treated and untreated leukemic mice,
however, a significant (P<0.05) decrease
was apparent in the statolon treated
group. The mean autopsy spleen weight
of statolon treated leukemic mice was
43% less than that of the untreated
leukemic controls.
Interferon Production in Response to Statolon
Treatment and Rauscher Virus
The levels of interferon, induced in
leukemic and control mice with statolon
preceding and following hematopoietic
cell transplantation, (see table 3) show
that 7 days after RLV inoculation there
was no production of interferon in the
leukemic mice in response to the Rauscher
virus. On day 14, 23 hours following
statolon injection and prior to irradiation
and transplantation, maximal interferon
production was observed in the control
mice. Only 0.1 of the interferon produc-
tion observed in the control mice was ob-
served in the leukemic mice. Apparently
the production of interferon was sup-
pressed in these animals by the viral
leukemia. On days 21 and 30, there was
still no detectable production of interferon
in the leukemic mice due to the virus. In
the control mice on day 30, but not in the
leukemic mice, a small amount of inter-
feron was produced following the injec-
tion of statolon on day 29.
TABLE 3
Interferon production in statolon inoculated*
Rauscher leukemic (RL V) and control mice
preceding and following hematopoietic cell
transplantation. * *
Days after
RLV Inject.
7
14
21
30
Interferon Titerf
Control
Rauscher
Leukemic
0
3,160
0
10
0
316
0
0
*Statolon was injected on days 13 and 29.
**1100 R irradiation and spleen cell transplant
occurred on day 14.jlnterferon titers are expressed as reciprocols
of the highest dilution of the serum em-
ployed, 1 ml of which protected cultures
against challenge with standard doses of
VSV. No serum was tested at less than
1:10 dilution.
Effect of Combination Therapy on Survival
Table 4 summarizes the survival data
of both the statolon treated and un-
treated control and viral infected mice at
30 days following 1100 R X-ray exposure
and spleen cell transplantation. Sur-
vival times were counted from the time
of irradiation and spleen cell transplanta-
tion, i.e 14 days after virus infection.
Among the untreated control and un-
treated leukemic mice, 94% and 64%
survival was observed at 30 days, re-
spectively. These values are approxi-
10% higher than those observed in an
TABLE 4
Effect of statolon on 30-day survival of 1100 R
irradiated and spleen cell transplanted
leukemic mice.
Treatment
No RLV*
No RLV+Statolon
RLV
RLV+Statolon
No. of
Mice
% 30-day
Survival
24
24
25
27
94
79
64
85
*RLV = Rauscher leukemia virus.
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earlier study under the same experimental
conditions (Kuhnert et al 1974). Thirty
day "rescue" was achieved in both the
control and leukemic mice; however, in
the control group treated with statolon, a
15% decrease in survival was observed
at 30 days. Apparently, treatment with
statolon decreased survival time in this
experimental group. On the other hand,
Rauscher leukemic mice treated with
statolon showed a 21% increase in sur-
vival over the untreated leukemic mice.
DISCUSSION
From our data, it is clear that a positive
response was observed on all of the in-
dices of leukemia development investi-
gated. These responses included a 42%
decrease in spleen weight at autopsy, a
21% increase in survival at 30 days, and
significantly decreased white blood cell
counts and spleen weight during the
treatment period. The effect of the
combination therapy was not permanent,
however, and the mice eventually suc-
cumbed to the viral leukemia.
The statolon dose used in the present
study (5 mg/mouse) was chosen because
it has been successfully used to induce
interferon formation in mice (Wheelock
1967, Wheelock et al 1974) and because a
preliminary study by us showed that it
was capable of inducing large amounts of
interferon in the SJL/J mouse. At this
dosage level, no adverse effects have been
reported but our data indicate that this
dose is toxic in nonleukemic mice that
have been treated with irradiation and
transplantation. The toxic effects ob-
served included a 15% decrease in 30-
day survival and decreases in white
blood cell counts and mean autopsy
spleen weight. These side effects may,
of course, be apparent in this investiga-
tion because of the unique experimental
conditions. Unfortunately, little infor-
mation is available concerning the toxic-
ity of statolon to mice (Finter 1973).
Our experimental mice were injected
with statolon at 2 propitious times dur-
ing the course of the treatment protocal.
The first injection was given 20 hours
prior to irradiation and hematopoietic
cell transplantation. This time was
chosen because preliminary experiments
showed that interferon production
reached a peak in the SJL/J mouse at
approximately 15 hours after statolon
injection and did not begin to decline un-
til 25 hours after injection. Therefore,
the maximum titer of interferon would
be present when the hematopoietic system
was destroyed by irradiation and the
donor hematopoietic cells were inocu-
lated. By producing a high titer of in-
terferon at this time, viral transformation
of the donor hematopoietic cells may be
theoretically blocked. The time of the
second statolon injection was chosen for
its therapeutic potential. De Maeyer et
al (1967) had shown that interferon pro-
duction was restored in lethally irradiated
mice grafted with bone marrow cells 15
days after irradiation and transplanta-
tion. Thus, the second injection of
statolon was given on the 15th day follow-
ing irradiation and transplantation.
In response to the injection of statolon,
Rauscher leukemic mice in the present
study produced only low titers of circulat-
ing interferon. This suppression of in-
terferon production has been reported
by other investigators and is apparently
an effect of the mouse leukemia viruses.
According to Vandeputte et al (1967),
mice inoculated with Rauscher virus no
longer produce interferon in response to
challenge with a heterologous virus.
Similarly, Friend leukemic mice produce
little or no interferon when induced by
Sendai virus between 1 and 10 days after
Friend virus inoculation (Wheelock and
Larke 1968), but 12 days after Friend
virus inoculation, normal levels of inter-
feron may be produced. Wheelock et al
(1969) showed that mice injected with
statolon 3 days after Friend virus inocu-
lation produced as much circulating in-
terferon as normal mice. These studies
and our investigation suggest that a gen-
eral statement cannot be made regarding
the induction of interferon in viral leu-
kemic mice. Several factors apparently
influence the response of leukemic mice
to interferon inducing agents; these
factors include the inducing agent, the
strain of mice, and the stage of leukemia
development.
It is also apparent from our data that
the Rauscher leukemia virus itself did
not induce interferon formation. This
lack of response to Rauscher leukemia
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virus has been observed by others.
Pieries et al (1965) reported that BALB/c
mice produced no interferon when in-
fected with Rauscher virus, and Vande-
putte et al (1967) could not detect in-
terferon in the enlarging livers and
spleens of NIMR and albino Swiss mice
at various times from 16 hours to 14
days after infection with Rauscher virus.
The effectiveness of the combination
therapy utilized in our investigation is
apparent from the decreased WBC pro-
duction and spleen weight and increase
in 30-day survival time. These effects
were observed in addition to those ob-
served when treating leukemic mice with
lethal whole-body irradiation and hema-
topoietic cell transplantation alone. They
may be attributable to the use of statolon
to induce interferon production in the
leukemic mice but it must be noted that
the production of interferon in the leu-
kemic mice was low. In fact, interferon
production in the leukemic mice was only
0.1 the amount produced in the control
mice. These results suggest that other
effects of statolon therapy in addition to
interferon production contributed to the
effectiveness of the combination therapy.
There is evidence indicating that
statolon affects tumor inhibition through
other mechanisms besides the well docu-
mented method of interferon induction
(Metz 1975). Weislow et al (1973) re-
ported that statolon abrogates the im-
munodepressive effects of Friend virus
and permits the infected mouse to mobi-
lize an effective humoral antibody re-
sponse to leukemic cells and Toy et al
(1973) tested several interferon inducing
agents and found statolon to be the only
agent capable of abrogating immuno-
depression and stimulating FV-cytotoxic
antibody. Other possible mechanisms
of tumor inhibition by statolon include
the release of a lymphotoxin from
lymphocytes, a mechanism reported for
the interferon inducer Poly I: poly C by
Dean et al (1972).
It is, of course, not possible to deter-
mine from our data which mechanism of
statolon action resulted in the decreased
rate of leukemia development. Addi-
tional studies are needed to clarify this
point and to determine if the injection of
interferon is more effective than the in-
duction of interferon. Nonetheless, our
studies indicate that combining statolon
therapy with irradiation and transplanta-
tion therapy is a promising approach to
treating viral leukemia.
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